Remicade Gets First-Line Rheumatoid Arthritis Claim On Data In Early Disease
This article was originally published in The Pink Sheet Daily
Executive Summary
J&J's infliximab is approved for first-line RA treatment in combination with methotrexate. Approval is based on 54-week ASPIRE trial showing superiority in early RA; study also shows preventative benefit in patients without initial joint damage.